SOCS3 and melanoma: Several clinical trials (NCT02646748 and NCT03012230) employing the JAK inhibitors in combination anti-PD-1 are underway, but early results have not been favorable.44 SOX2 is overexpressed in melanoma,45 genetic perturbation of SOX2 could promote the expression of PTPN1 and SOCS3 and feedback inhibition of JAK-STAT pathway, making SOX2 a promising target to control aberrant JAK-STAT activity.